Northern Lights Forecast: 15 States—Including New York—Could See Aurora Borealis Tonight
Strong geomagnetic storms could produce a northern lights show in about 15 states Monday night, according to a National Oceanic and Atmospheric Administration forecast, as a solar flare observed over the weekend has triggered powerful displays of aurora borealis.
The northern lights may be visible in more than a dozen states Monday night. (Photo by Patrick ... More Pleul/picture alliance via Getty Images)
NOAA forecast Monday night's aurora borealis could have a Kp index of five, the strength of the aurora borealis measured on a scale from zero to nine, indicating 'more auroral activity' that can be 'quite pleasing to look at.'
The northern lights are expected to be active Monday night because of strong geomagnetic storms, which NOAA forecasts will reach a level of G3 on a scale of G1 to G5, indicating 'strong' geomagnetic storms that will disturb the Earth's magnetic field.
These geomagnetic storms are linked to an Earth-bound solar flare that was emitted Friday, according to NOAA, which caused geomagnetic storms measured at a level of G4 on Sunday, indicating 'severe' strength.
Sunday night's northern lights forecast was especially strong, according to NOAA, with visibility projected for nearly two dozen states.
Strong northern lights conditions will continue this week, according to NOAA's three-day forecast, as lingering geomagnetic storms are expected Tuesday before decreasing in strength.
Alaskans and Canadians have the highest likelihood of seeing aurora borealis Monday night, according to NOAA's forecast. Other states with strong chances of seeing the northern lights include Washington, Idaho, Montana, North Dakota, South Dakota, Minnesota, Wisconsin and Michigan. States included along the aurora's 'view line,' the southernmost point at which likelihood of seeing the northern lights is the lowest, include Wyoming, Iowa, New York, New Hampshire, Vermont and Maine.
Monday night's northern lights forecast.
The northern lights will be easiest to see between about 10 p.m. and 2 a.m. local time, according to NOAA. The best way to view the lights is by avoiding light pollution, traveling as far north as possible and finding a high vantage point.
Travel photographers told National Geographic the best way to capture the northern lights is by using a wide-angle lens, as well as a tripod for stability. For iPhone users, the camera app's night mode can help make the lights more visible. Other tactics that can help produce a better image include using an aperture value of 4.0 or lower and adding details to the image by capturing trees, bodies of water or mountains.
The northern lights have been especially active over the past year because of increased solar activity, like geomagnetic storms and solar flares. NOAA said although this weekend's flare was especially strong, scientists do not expect geomagnetic storms associated with the flare to be as strong as in May 2024, when a series of powerful solar flares triggered severe geomagnetic storms and northern lights displays as far south as Florida. Scientists say the sun is currently in its 'solar maximum,' the period in its 11-year cycle during which it is most active, though this solar cycle has exceeded scientists' expectations: NASA estimated northern lights activity in 2024 reached a 500-year peak. NASA scientists said they expect strong aurora activity to continue throughout this year before declining in the latter part of the decade.
Northern Lights Displays Hit A 500-Year Peak In 2024—Here's Where You Could Catch Aurora Borealis In 2025 (Forbes)
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Southern Living says this small Georgia town serves as the Watermelon Capital of the World
Nestled in the heart of Georgia's farm country, lies a small town with a big title, the "Watermelon Capital of the World." Southern Living has just recently highlighted this small town calling it "home to farms, wide-open countryside, and more watermelons than you've likely seen in one place." See where. Located in Cordele, Georgia, there are fields of the iconic summer fruit. From here, watermelons are shipped across Georgia and beyond, feeding a region's appetite for this ultimate warm-weather treat. "'Watermelon Capital of the World, and if you ever taste our home-grown melons, you'll understand why!" the city's website wrote. "Other major crops grown in the area are cotton, peanuts and pecans." Cordele, Georgia is a small city located in Crisp County in south-central Georgia, about 140 miles or two hours south of Atlanta. This town serves as the county seat of Crisp County and is often referred to as the "Gateway to South Georgia." Its central location makes it a convenient stop for travelers heading to or from Florida, and it's best known for its rich agricultural roots, especially its watermelon production. According to World Population Review, this town has a population of just under 10,000. But Cordele is more than just melons. According to Southern Living, here are some things to do in this town: Take a scenic ride on a vintage train car Time your visit with the Watermelon Days Festival Go to the Georgia Veterans State Park Go golfing at the Memorial Golf Course Watch a race at the speedway Visit The Titan I Missile Monument For more information, visit Vanessa Countryman is the Trending Topics Reporter for the the Deep South Connect Team Georgia. Email her at Vcountryman@ This article originally appeared on Savannah Morning News: Where is the Watermelon Capital of the World? More about Cordele, GA
Associated Press
39 minutes ago
- Associated Press
Novo Nordisk advances early-stage obesity medication, amycretin, to phase 3 clinical development based on early-phase clinical trial results in people with obesity or excess weight, published in The Lancet
PLAINSBORO, N.J., June 20, 2025 /PRNewswire/ -- Today, results from two early-phase clinical trials evaluating Novo Nordisk's amycretin, an innovative investigational obesity treatment designed to target appetite regulation, were published in The Lancet.1 In a phase 1b/2a clinical trial of 125 adults with overweight or obesity, once-weekly subcutaneous amycretin appeared to be safe and tolerable in trial participants, who also achieved significantly greater weight loss across the full range of doses investigated versus placebo.1 A related phase 1 trial of once-daily oral amycretin in adults with obesity or overweight also showed that treatment was safe and tolerable with an observed reduction in body weight compared to placebo.2 No weight loss plateau was observed in either trial at the end of the respective treatment durations.1,2 Data on subcutaneous amycretin is scheduled to be presented on Sunday, June 22nd, during a late-breaking poster session at the American Diabetes Association's® (ADA) 85th Scientific Sessions.1 'We are pleased with the promising results of amycretin and the feedback from regulatory authorities and are excited to advance both subcutaneous and oral versions of this molecule into phase 3 development for weight management. At Novo Nordisk, we understand that addressing obesity is a complex challenge that many patients face. These results reflect our robust pipeline in obesity, our focus on progressing scientific innovation and expanding the range of options available to patients and healthcare professionals,' said Martin Holst Lange, executive vice president for Development at Novo Nordisk. 'We remain steadfast in our mission to discover and develop therapies that can have a meaningful impact in the lives of those affected by obesity.' Results from the phase 1b/2a trial of subcutaneous amycretin showed treatment-emergent adverse events (TEAEs) were mild or moderate in severity and increased in frequency in a dose-dependent manner. The most frequent reported TEAEs were gastrointestinal in nature. Compared to placebo, participants receiving amycretin observed greater weight loss across the full range of doses investigated.1 Subcutaneous amycretin at multiple doses demonstrated greater weight reduction than placebo at the end of the trial. Participants who received the highest doses (up to 60 mg) reported body weight reductions of up to 24.3% versus 1.1% with placebo after 36 weeks of treatment. Results from this first-in-human phase 1b/2a study support further investigation of potential weight-loss efficacy of amycretin. Results from the published phase 1 trial of oral amycretin showed that the most common TEAEs were related to gastrointestinal symptoms (mainly nausea and vomiting) and decreased appetite; these were most frequent for the higher doses. Trial participants receiving the study treatment demonstrated significantly greater weight loss across the full range of doses investigated versus the placebo group.2 Exploratory results showed participants taking 100 mg per day of oral amycretin achieved a mean weight loss of 13.1% versus 1.2% with placebo after 12 weeks.2 Based on these phase 1 results, longer evaluation with more participants is warranted to substantiate the full efficacy findings of oral amycretin on body weight reductions and changes in metabolic parameters. Novo Nordisk will advance both subcutaneous and oral amycretin formulations straight to phase 3 development for weight management based on these and other completed clinical studies, as well as feedback received from regulatory authorities. About amycretin Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide a treatment for adults with overweight or obesity and as a treatment for adults with type 2 diabetes. Amycretin is under investigation for oral and subcutaneous administration, and is not approved in the US for weight loss. About the phase 1b/2a subcutaneous amycretin trial The phase 1b/2a trial was a randomized, placebo-controlled, single-center, double-blinded study of 125 participants assessing the safety, tolerability, pharmacokinetics, and effects on body weight after subcutaneous administration of amycretin in people with overweight or obesity.1 Adults with a body mass index of 27-39.9kg/m2 and glycated hemoglobin (HbA1c) <6.5% were eligible for the trial.1 The trial was conducted in 5 parts: a single ascending dose (Part A) for determination of pharmacokinetics and starting dose for the first multiple dose cohort in which the safety and tolerability were explored using dose escalation until 36 weeks of total treatment duration (Part B).1 Lastly, in the multiple ascending dose – dose response parts, body weight loss was explored for up to 36 weeks of dosing by escalating to dose levels of 1.25 mg, 5 mg, and 20 mg, respectively, dosed for 12 weeks (Part E, D and C).1 About the phase 1 oral amycretin trial The phase 1 single-center, randomized, placebo-controlled study evaluated the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses (Part A) and multiple ascending doses (Part B, 10 days of treatment; Part C/D, 12 weeks of treatment) of 144 adult participants with overweight or obesity.2 The primary endpoint was the number of treatment-emergent adverse events (TEAEs) observed in the trial. The trial evaluated the single-ascending dose and multiple ascending doses for oral amycretin, up to 2 times 50 mg, in people with overweight or obesity, with a total treatment duration of up to 12 weeks.2 About obesity Obesity is a serious chronic, progressive, and complex disease that requires long-term management.3-5 One key misunderstanding is that this is a disease of just lack of willpower, when in fact there is underlying biology that may impede people with obesity from losing weight and keeping it off.3,5 Obesity is influenced by a variety of factors, including genetics, social determinants of health, and the environment.6,7 The prevalence of overweight and obesity is a public health issue that has severe cost implications to healthcare systems.8,9 In the US, about 40% of adults live with obesity.10 About Novo Nordisk Novo Nordisk is a leading global healthcare company that's been making innovative medicines to help people with diabetes lead longer, healthier lives for more than 100 years. This heritage has given us experience and capabilities that also enable us to drive change to help people defeat other serious chronic diseases such as obesity, rare blood, and endocrine disorders. We remain steadfast in our conviction that the formula for lasting success is to stay focused, think long-term, and do business in a financially, socially, and environmentally responsible way. With a US presence spanning 40 years, Novo Nordisk US is headquartered in New Jersey and employs over 10,000 people throughout the country across 12 manufacturing, R&D and corporate locations in eight states plus Washington DC. For more information, visit Facebook, Instagram, and X. Novo Nordisk is committed to the responsible use of our semaglutide-containing medicines which represent distinct products with different indications, dosages, prescribing information, titration schedules, and delivery forms. These products are not interchangeable and should not be used outside of their approved indications. Learn more at Contacts for further information References © 2025 Novo Nordisk All rights reserved. US25SEMO01477 June 2025 View original content to download multimedia: SOURCE NOVO NORDISK INC.
Associated Press
39 minutes ago
- Associated Press
MountBay Energy Unlocks Microbial Biofilm Technology to Revolutionize Battery Longevity
NEW YORK, June 21, 2025 (GLOBE NEWSWIRE) -- MountBay Energy has unveiled groundbreaking research on microbial biofilms that could redefine the future of grid-scale energy storage. The study, led by founder Vrushabhraj Tanawade, introduces a bio-integrated insulation method using thermophilic and mesophilic microbial consortia to regulate heat inside battery modules. The results are striking: up to a 22% reduction in internal temperature and a 30% improvement in carbon lifecycle efficiency. 'This innovation is about biology meeting infrastructure,' says Tanawade. 'We've discovered how nature's mechanisms can dramatically extend the life of our clean energy systems.' Unlike conventional synthetic cooling solutions, MountBay's microbial approach is circular, biodegradable, and scalable—opening up new frontiers for climate resilience and fire-risk reduction in hot environments. The research aligns perfectly with MountBay's mission to power the AI economy through clean, sustainable, and advanced infrastructure. It also positions the company as a frontrunner in biological material integration across the energy sector. Additionally, MountBay has released a preliminary transformative feasibility report for a Lunar Solar Belt—a continuous solar array on the Moon that can beam uninterrupted, clean energy back to Earth. The report outlines how in-situ resource utilization (ISRU), autonomous lunar robotics, and microwave power transmission could enable the construction of a moon-based solar plant by the 2030s. With an energy return on investment (EROI) of 8:1, the system offers a scalable, emission-free solution to humanity's growing power demands. 'This is not just an energy project—it's a civilization-scale investment in global stability,' said Tanawade. 'We believe the Moon should be a cooperative utility, not a geopolitical race.' MountBay is also proposing a new diplomatic framework—The Earth-Moon Energy Accord (EMEA)—to ensure equitable access, safety, and international cooperation. The concept directly supports MountBay's mission: to push the frontiers of clean power while securing energy independence for AI-driven economies. Tanawade is rallying governments, institutions, and innovators to join him. 'It's time for America to lead the most ambitious energy project in human history,' he said. Media Contact: Vrushabhraj Tanawade Founder @ MountBay Energy Contact : [email protected] Website: Linkedin: Linkedin - Vrushabhraj T Disclaimer: This press release is provided by MountBay Energy. The statements, views, and opinions expressed are solely those of the provider and do not necessarily reflect those of this media platform or its publisher. Any names or brands mentioned are used for identification purposes only and remain the property of their respective owners. No endorsement or guarantee is made regarding the accuracy, completeness, or reliability of the information presented. This material is for informational purposes only and does not constitute financial, legal, or professional advice. Readers are encouraged to conduct independent research and consult qualified professionals. The publisher is not liable for any losses, damages, or legal issues arising from the use or publication of this content. Photos accompanying this announcement are available at:
